Cytomx Therapeutics, Inc. (CTMX) Stock Price & Analysis
Cytomx Therapeutics, Inc. (CTMX) fell 2.70% to USD 3.24 as of July 25, 2026 at 03:41 UTC, according to Nexqual real-time market data.
CTMX last closed at USD 3.33; the session ranged USD 3.2–3.38 on volume of 1,483,818 shares. Market capitalization is $705.36M, with a 52-week range of USD 1.72–8.21 (NMS). Source: Nexqual, July 25, 2026 at 03:41 UTC.
Key Statistics (as of July 25, 2026 at 03:41 UTC)
| Price | USD 3.24 |
|---|---|
| Change | ▼ 2.70% (down) |
| Previous Close | USD 3.33 |
| Open | USD 3.34 |
| Day Range | USD 3.2 – 3.38 |
| 52-Week Range | USD 1.72 – 8.21 |
| Volume | 1,483,818 shares |
| Market Cap | $705.36M |
| Exchange | NMS |
Technical Analysis (CTMX)
Nexqual's technical model rates CTMX "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:41 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.49 (neutral) |
| vs SMA50 | Below (USD 3.45) |
| MACD | -0.03 (negative) |
Analyst Ratings (CTMX)
Wall Street analysts rate CTMX "None" based on 8 analysts, with a mean price target of USD 12.5 (range USD 6–16), per Nexqual as of July 25, 2026 at 03:41 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 12.5 |
| High Target | USD 16 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (CTMX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.1 |
| Revenue Estimate | $12.34M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.1 vs est -0.11 ▲ beat |
| 2025-12-31 | USD -0.22 vs est -0.09 ▼ miss |
| 2025-09-30 | USD -0.09 vs est -0.04 ▼ miss |
| 2025-06-30 | USD 0 vs est -0.06 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Financials & Fundamentals (CTMX)
| Total Revenue | $35.54M |
|---|---|
| Revenue Growth (YoY) | -79.90% |
| Gross Margin | +100.00% |
| Operating Margin | -191.77% |
| Profit Margin | -166.40% |
| ROE | -34.28% |
| Debt / Equity | 0.89 |
| Current Ratio | 10.38 |
| Total Cash | $346.71M |
| Total Debt | $2.86M |
| Free Cash Flow | $-41.91M |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Financial Health Score (CTMX)
Nexqual rates Cytomx Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:41 UTC.
| Growth | Critical — Revenue -45% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $347M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$42M, burning cash |
| Efficiency | Critical — ROE -34%, ROA -16.9% |
Ownership (CTMX)
| Insider Ownership | +0.53% |
|---|---|
| Institutional Ownership | +96.40% |
| Shares Outstanding | 217.70M |
| Float | 186.26M |
| Short % of Float | +18.54% |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Leadership (CTMX)
Cytomx Therapeutics, Inc. is led by Sean A. McCarthy DPHIL (age 58), Chairman & CEO, per Nexqual as of July 25, 2026 at 03:41 UTC.
| Chairman & CEO | Sean A. McCarthy DPHIL (age 58) |
|---|---|
| SVP, CFO & Secretary | Christopher W. Ogden (age 41) |
| Senior VP & Chief Scientific Officer | Marcia P. Belvin (age 58) |
| Senior Vice President of Intellectual Property | Leslie Robbins |
| Senior Vice President of Quality & Product Manufacturing | Dawn Benson |
Major Backers & Investors (CTMX)
Notable institutional backers of Cytomx Therapeutics, Inc. include FMR, LLC, Fidelity, Kynam Capital Management, LP, according to Nexqual as of July 25, 2026 at 03:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.68% |
| Fidelity | 9.91% |
| Kynam Capital Management, LP | 6.9% |
| Bank of America Corporation | 4.69% |
| Perceptive Advisors Llc | 4.64% |
| Venrock Adviser, LLC | 4.59% |
| Point72 Asset Management, L.P. | 3.62% |
| Citadel | 2.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.93% |
| State Street | 6.24% |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
From Cytomx Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
- The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
- It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.
- In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MGNX | MacroGenics, Inc. | USD 3.7 | ▼ 13.95% |
| KALA | KALA BIO, Inc. | USD 0.63 | ▼ 13.95% |
| ASMB | Assembly Biosciences, Inc. | USD 25.55 | ▼ 1.88% |
| CRVS | Corvus Pharmaceuticals, Inc. | USD 13.07 | ▼ 6.58% |
| ATRA | Atara Biotherapeutics, Inc. | USD 7.9 | ▼ 2.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:41 UTC. This page is informational and not investment advice.